Posted by Michael Wonder on 23 Aug 2023
FDA grants priority review for Xtandi in non-metastatic castration sensitive prostate cancer with high risk biochemical recurrence
23 August 2023 - If approved, Xtandi would become the first and only novel hormone therapy approved in this earlier type of prostate cancer
Pfizer and Astellas Pharma today announced that the US FDA has accepted and granted priority review for the companies' supplemental new drug application for Xtandi (enzalutamide) for the treatment of patients with non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.
